REC3 - Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson IM, Narayan V, George DJ, Heng DYC, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason GA, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara PN, Lerner SP, Balzer-Haas N, Pal SK. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal of Clinical Oncology 42: 3911-3916. 2024.
This randomized phase II trial studied how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Survival Outcomes
A total of 152 patients were randomly assigned 1:1:1:1 to the four arms. After five patients were excluded because of no evidence of metastatic disease, 147 patients remained evaluable, with 46, 44, 28, and 29 patients assigned to receive sunitinib, cabozantinib, crizotinib, and savolitinib, respectively. The median follow-up was 17.5 months in this report.
Registry Results: NCT02761057: Study results are available on www.clinicaltrials.gov
BR34 - Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR34 trial
Annageldiyev C, Gaudreau P-O, Leitzel K, Ali SM, Ding K, Leighl NB, Badillo FEV, Bradbury PA, Goss GD, Shepherd LE, Costa L, Suva LJ, Hughes BGM, Stockler MR, Drabick JJ, Ma PC, Joshi M, Moku P, Polimera HA, Louis P, Ramachandrula P, Lipton A. Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial (ONLINE). JCO Oncology Advances e2400017. 2024.